FBIO - Fortress Biotech, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
FBIO price evolution
FBIO
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $78.26 | $85.84 | $83.36 | |
| Short term investments | ||||
| Net receivables | $10.85 | $10.69 | $10.12 | $15.39 |
| Inventory | $11.79 | $9.69 | $10.58 | $10.21 |
| Total current assets | $86.28 | $103.44 | $116.55 | $117.02 |
| Long term investments | ||||
| Property, plant & equipment | $17.55 | $18.17 | $22.59 | $23.5 |
| Goodwill & intangible assets | $18.66 | $19.47 | $20.29 | |
| Total noncurrent assets | $42.25 | $48.1 | $50.5 | |
| Total investments | ||||
| Total assets | $127.08 | $145.69 | $164.65 | $167.53 |
| Current liabilities | ||||
| Accounts payable | $50.51 | $68.92 | $76.38 | $73.56 |
| Deferred revenue | ||||
| Short long term debt | $2.48 | $6.62 | $6.45 | |
| Total current liabilities | $70.31 | $75.54 | $87.7 | $84.91 |
| Long term debt | $52.47 | $82.94 | $79.04 | $79.14 |
| Total noncurrent liabilities | $84.74 | $80.89 | $81.03 | |
| Total debt | $85.42 | $85.66 | $85.59 | |
| Total liabilities | $105.93 | $160.28 | $168.58 | $165.94 |
| Shareholders' equity | ||||
| Retained earnings | -$734.1 | -$721.24 | -$710.29 | -$694.87 |
| Other shareholder equity | ||||
| Total shareholder equity | $17.88 | $23.02 | $22.54 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $83.36 | $180.95 | $307.96 | $235 |
| Short term investments | ||||
| Net receivables | $15.39 | $28.35 | $23.79 | $20.09 |
| Inventory | $10.21 | $14.16 | $9.86 | $1.4 |
| Total current assets | $117.02 | $230.43 | $346.46 | $261.57 |
| Long term investments | $17.57 | |||
| Property, plant & equipment | $23.5 | $33.01 | $34.07 | $32.41 |
| Goodwill & intangible assets | $20.29 | $27.2 | $12.55 | $14.63 |
| Total noncurrent assets | $50.5 | $63.87 | $50.04 | $67.26 |
| Total investments | $17.57 | |||
| Total assets | $167.53 | $294.3 | $396.5 | $328.83 |
| Current liabilities | ||||
| Accounts payable | $73.56 | $77.1 | $90.66 | $40.67 |
| Deferred revenue | $0.73 | $2.61 | ||
| Short long term debt | $6.45 | $5.39 | $2.92 | $7.15 |
| Total current liabilities | $84.91 | $127.72 | $101.04 | $47.96 |
| Long term debt | $79.14 | $93.14 | $63.92 | $81.93 |
| Total noncurrent liabilities | $81.03 | $116.56 | $69.58 | $83.88 |
| Total debt | $85.59 | $118.7 | $66.84 | $89.08 |
| Total liabilities | $165.94 | $252.58 | $170.63 | $131.84 |
| Shareholders' equity | ||||
| Retained earnings | -$694.87 | -$634.23 | -$547.46 | -$482.76 |
| Other shareholder equity | $96.66 | |||
| Total shareholder equity | $22.54 | $41.72 | $108.67 | $100.34 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $14.63 | $14.9 | $13.03 | $19.95 |
| Cost of revenue | $6.54 | $6.82 | $6.01 | |
| Gross Profit | $9.34 | $8.36 | $6.21 | $13.93 |
| Operating activities | ||||
| Research & development | $12.67 | $24.84 | $14.08 | |
| Selling, general & administrative | $20.82 | $17.94 | $22.61 | |
| Total operating expenses | $31.44 | $36.14 | $42.78 | $33.55 |
| Operating income | -$27.79 | -$36.57 | -$19.61 | |
| Income from continuing operations | ||||
| EBIT | -$8.83 | -$12.81 | -$6.84 | |
| Income tax expense | $0.07 | $0.38 | ||
| Interest expense | -$5.6 | $2.12 | $2.6 | $2.06 |
| Net income | ||||
| Net income | -$15.04 | -$10.95 | -$15.42 | -$9.28 |
| Income (for common shares) | -$13.34 | -$17.73 | -$11.29 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $84.51 | $75.74 | $68.79 | $45.6 |
| Cost of revenue | $26.66 | $30.77 | $32.08 | $14.59 |
| Gross Profit | $57.85 | $44.97 | $36.71 | $31 |
| Operating activities | ||||
| Research & development | $106.07 | $134.88 | $128.87 | $64.11 |
| Selling, general & administrative | $94.12 | $113.66 | $86.84 | $61.17 |
| Total operating expenses | $200.19 | $248.53 | $225.25 | $125.28 |
| Operating income | -$142.34 | -$203.56 | -$188.54 | -$94.27 |
| Income from continuing operations | ||||
| EBIT | -$44.8 | -$72.48 | -$48.92 | -$31.06 |
| Income tax expense | $0.52 | $0.45 | $0.47 | $0.14 |
| Interest expense | $15.31 | $13.64 | $15.31 | $15.33 |
| Net income | ||||
| Net income | -$60.64 | -$86.58 | -$64.7 | -$46.53 |
| Income (for common shares) | -$68.67 | -$86.58 | -$64.7 | -$46.53 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$10.95 | -$15.42 | -$9.28 | |
| Operating activities | ||||
| Depreciation | $2.56 | $1.72 | $1.71 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5 | $4.86 | $3.7 | |
| Total cash flows from operations | -$21.84 | -$25.39 | -$34.94 | |
| Investing activities | ||||
| Capital expenditures | -$0.03 | |||
| Investments | ||||
| Total cash flows from investing | -$0.06 | |||
| Financing activities | ||||
| Dividends paid | -$4.54 | |||
| Sale and purchase of stock | $1.98 | $11.01 | $8.81 | |
| Net borrowings | $5 | $14.62 | ||
| Total cash flows from financing | $44.84 | $14.27 | $27.86 | $43.62 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$22.45 | -$7.57 | $2.47 | $8.62 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$60.64 | -$86.58 | -$64.7 | -$46.53 |
| Operating activities | ||||
| Depreciation | $8.07 | $5.08 | $4.32 | $3.9 |
| Business acquisitions & disposals | -$20 | $56.86 | ||
| Stock-based compensation | $17.03 | $22.99 | $19.49 | $13.45 |
| Total cash flows from operations | -$128.22 | -$179.4 | -$116.54 | -$83.68 |
| Investing activities | ||||
| Capital expenditures | $5.94 | -$2.59 | -$4.97 | -$3.13 |
| Investments | ||||
| Total cash flows from investing | -$2.1 | -$22.93 | $40.51 | -$7.16 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $24.12 | $4.53 | $9.36 | $46.03 |
| Net borrowings | -$39 | $48.65 | -$9.73 | -$34.12 |
| Total cash flows from financing | $32.74 | $75.32 | $148.99 | $172.41 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$97.59 | -$127.01 | $72.97 | $81.56 |
News
Fundamentals
| Market cap | $50.20M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 27.58M |
| Revenue | $62.50M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$50.68M |
| Revenue Q/Q | -57.90% |
| Revenue Y/Y | -22.81% |
| P/E ratio | -0.99 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.80 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.84 |
|---|---|
| ROA | -33.51% |
| ROE | N/A |
| Debt/Equity | 7.36 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.23 |
| Quick ratio | 1.06 |